KL research project honoured with highly endowed research prize

^{From left to right: KL medical student Michael Schranz BSc, Primar Josef Singer, Head of the Clinical Department of Internal Medicine 2, Krems University Hospital, Dr Ruchi Paroha MSc}

At this year's presentation of the Creating Possible Award 2025 of the biotech company Gilead Sciences, the research project "The Role of NKG2D-Ligands in Clinical Oncology" at Karl Landsteiner University (KL) was honoured with one of the five coveted prizes, each worth 25,000 euros. The award recognises outstanding initiatives that pursue innovative approaches to improving healthcare in Austria. With this project, the KL team - Prim. Clin.Assoc.Prof. Priv.Doz. Dr Josef Singer, PhD, MBA, Head of the Clinical Department of Internal Medicine 2 at Krems University Hospital, Dr Ruchi Paroha MSc and KL medical student Michael Schranz, BSc - was successful against numerous high-calibre submissions.

The award-winning research project is dedicated to the role of NKG2D ligands - important surface molecules of the immune system - and investigates their significance for the course and effectiveness of modern oncological therapies. Through new insights into the interaction of tumour cells and immunological activation mechanisms, the project makes a valuable contribution to the further development of targeted cancer treatments. The jury particularly emphasised the translationally oriented study design, which builds bridges between basic research and clinical application.

A strong signal for oncological research in Lower Austria

This success once again emphasises the growing importance of Lower Austrian research institutions in national and international oncology. The award not only honours scientific excellence, but also strengthens the visibility of innovative research projects that contribute to improving patient care in the long term.

We would like to congratulate the entire research team on this achievement!